Filing Flows › Azenta (AZTA) › Q3 FY26 › vs Q3 FY25
Azenta (AZTA) Q3 FY26 vs Q3 FY25 (year over year)
Azenta's revenue rose $17.3M (+12%) from $144M in Q3 FY25 to $161M in Q3 FY26. The biggest changes: Sample Management Solutions +$10.7M (+14%); Multiomics +$6.7M (+10%).
Azenta, Q3 FY26: revenue $161M (+12% year over year), operating margin -2.6%, net earnings $2.5M, operating cash flow $1.4M. The chart draws each line against Q3 FY25, the increases inside each band.
Every line
| Line | Q3 FY26 | Q3 FY25 | Change | % |
|---|---|---|---|---|
| Core Products | $47.7M | $45.7M | $2.0M | +4% |
| Sample Repository Services | $40.6M | $32.0M | $8.7M | +27% |
| Sample Management Solutions | $88.3M | $77.6M | $10.7M | +14% |
| Multiomics | $72.9M | $66.2M | $6.7M | +10% |
| Revenue | $161M | $144M | $17.3M | +12% |
| Other income, net | $9.0M | −$43.5M | $52.5M | — |
| Costs & expenses | $170M | $192M | −$21.7M | -11% |
| Operating costs | $165M | $146M | $19.7M | +13% |
| Income tax | $2.4M | $2.6M | −$260K | -10% |
| Net earnings | $2.5M | −$48.0M | $50.4M | — |
| Cost of revenue | $88.8M | $77.5M | $11.4M | +15% |
| Research & development | $8.9M | $7.4M | $1.4M | +19% |
| SG&A | $67.2M | $60.1M | $7.1M | +12% |
| Other operating costs | $513K | $754K | −$241K | -32% |
| Operating cash sources | $20.8M | −$30.0M | $50.9M | — |
| Depreciation & amortization | $13.6M | $14.7M | −$1.1M | -8% |
| Share-based compensation | $4.8M | $3.3M | $1.5M | +47% |
| Working capital & other | $19.4M | −$55.8M | $75.2M | — |
| Operating cash flow | $1.4M | $25.8M | −$24.4M | -94% |
| Capital expenditures | $6.6M | $10.8M | −$4.2M | -39% |
| Negative free cash flow (OCF − capex) | $5.2M | −$15.0M | $20.2M | — |
Questions
How much did Azenta's revenue grow year over year in Q3 FY26?
Azenta's revenue rose $17.3M (+12%) from $144M in Q3 FY25 to $161M in Q3 FY26.
What drove Azenta's revenue change in Q3 FY26?
Sample Management Solutions +$10.7M (+14%); Multiomics +$6.7M (+10%).